Drug Development
PBT-3 caused long-term growth inhibition of K562 solid tumors in vivo
Published in Blood Weekly, January 26th, 2006
"We demonstrate herein that daily administration of PBT-3 for 8 days to NU/NU mice bearing solid tumors derived from the s.c. administration of the leukemic cell line K562 results in inhibition of growth of the tumors in vivo, and this inhibition lasts for 60 days after stopping treatment with PBT-3 before recovery of tumor growth is reestablished," scientists reported in the journal Biochemical and Biophysical Research Communications.
"Similar findings were observed when the mice were treated with Gleevec (STI-571)," added X. Li and colleagues, Hospital for...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2006-01-26)
More Articles from Blood Weekly
- Blood Safety
Prevalence of parvovirus B19 and hepatitis A virus determined in Portuguese blood donors - Complementary & Alternative Medicine
Effective alternative treatment to resurface major burns presented - Stem Cell Transplantation
Transplanted HSCs and BM stromal cells promote recovery in injured spinal cord - Transplant Medicine
New filter system is developed for umbilical cord blood banking for transplantation - Transplant Medicine
Unrelated donor-BMT can cure more than two-thirds of adult thalassemia patients - Acute Myeloid Leukemia
MRP3, BCRR and P-glycoprotein activities can prognosticate leukemia - More from this issue of Blood Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
